Panel Lays Out Guidelines for CRISPR-Edited Human Embryos

The International Commission on the Clinical Use of Human Germline Genome Editing claims the technology is still too risky for therapeutic use.

Written byLisa Winter

| 2 min read

Listen with Speechify

0:00

2:00

ABOVE: © ISTOCK.COM, POSTERIORI

On Thursday (September 3), the International Commission on the Clinical Use of Human Germline Genome Editing released a report that reviews the available research and determines gene editing’s ethical use on human embryos. The 225-page document offers a roadmap to the testing and regulations necessary to develop the technology and ultimately concludes that the technology is not yet reliable enough to use on humans. Any country that permits its scientists to do so in the future should limit the activity to severe single-gene diseases.

The commission, composed of dozens of scientists worldwide, was formed after Chinese geneticist He Jiankui claimed in 2018 to have used CRISPR-Cas9 on a set of twins and a third baby to make them HIV-resistant. While the validity of the editing has yet to be determined, He’s claims have been met with international condemnation and a three-year prison sentence for illegally practicing ...

Interested in reading more?

The Scientist ARCHIVES

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!

Join for free today

Already a member? Login Here

Meet the Author

Lisa Winter
Lisa joined The Scientist in 2017. As social media editor, some of her duties include creating content, managing interactions, and developing strategies for the brand’s social media presence. She also contributes to the News & Opinion section of the website. Lisa holds a degree in Biological Sciences with a concentration in genetics, cell, and developmental biology from Arizona State University and has worked in science communication since 2012.
View Full Profile